NexgenRx Inc. (TSXV:NXG)

Canada flag Canada · Delayed Price · Currency is CAD
0.3000
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT
50.00%
Market Cap 20.98M
Revenue (ttm) 16.11M
Net Income (ttm) 254.52K
Shares Out 71.12M
EPS (ttm) 0.00
PE Ratio 89.61
Forward PE n/a
Dividend 0.01 (3.39%)
Ex-Dividend Date Apr 25, 2025
Volume n/a
Average Volume 48,026
Open 0.3000
Previous Close 0.3000
Day's Range 0.3000 - 0.3000
52-Week Range 0.2000 - 0.3500
Beta 0.53
RSI 58.71
Earnings Date Mar 28, 2025

About NexgenRx

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. The company also provides ancillary services. TNexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada. [Read more]

Sector Healthcare
Founded 2003
Employees 20
Stock Exchange TSX Venture Exchange
Ticker Symbol NXG
Full Company Profile

Financial Performance

In 2023, NexgenRx's revenue was 13.85 million, an increase of 8.33% compared to the previous year's 12.78 million. Losses were -331,970, 1381.9% more than in 2022.

Financial Statements

News

NexgenRx (NXG) Maintains Quarterly Dividend

NexgenRx (NXG) Maintains Quarterly Dividend

6 days ago - GuruFocus

NexgenRx declares CAD 0.005 dividend

6 days ago - Seeking Alpha

NexgenRx Announces Declaration of Divdend

TORONTO, ON / ACCESS Newswire / April 17, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been de...

6 days ago - Accesswire

Nexgenrx reports FY results

20 days ago - Seeking Alpha

NexgenRx Announces 2024 Year End Results with Continued Strong Revenue Growth and Increasing Positive EBITDA

TORONTO, ON / ACCESS Newswire / April 3, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2024, with con...

20 days ago - Accesswire

NexgenRx Announces Third Quarter Results and Declaration of Divdend

TORONTO, ON / ACCESSWIRE / November 25, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2024, with quarterly r...

5 months ago - Accesswire

NexgenRX Announces Director Re-Appointment

TORONTO, ON / ACCESSWIRE / October 7, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the re-appointment of Charles Burns to its Board of Directors effective immediately.

7 months ago - Accesswire

NexgenRx Announces New Director

TORONTO, ON / ACCESSWIRE / October 1, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the appointment of Linda Brennan to its Board of Directors effective immediately.

7 months ago - Accesswire

NexgenRx Announces Second Quarter Results, With Over 19% Revenue Growth and Positive EBITDA

TORONTO, ON / ACCESSWIRE / August 15, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2024, with quarterly revenue...

8 months ago - Accesswire

NexgenRx Announces Share Issuances Under Consulting Agreement

TORONTO, ON / ACCESSWIRE / July 18, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the issuance of an aggregate of 195,312 common shares at a price of $0.32 in respect of th...

9 months ago - Accesswire

NexgenRx Announces Declaration of Dividend

NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding commo...

11 months ago - Accesswire

NexgenRx Announces First Quarter Results, with 24% Revenue Growth and Record Earnings

TORONTO, ON / ACCESSWIRE / May 17, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2024, with revenue of $4,292,73...

1 year ago - Accesswire

NexgenRx Announces Annual Meeting Results

TORONTO, ON / ACCESSWIRE / May 16, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was he...

1 year ago - Accesswire

NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA

TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continue...

1 year ago - Accesswire

NexgenRx Announces Director Resignation

TORONTO, ON / ACCESSWIRE / December 29, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") announces the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive ro...

1 year ago - Accesswire

NexgenRX Announces Declaration of Dividend

TORONTO, ON / ACCESSWIRE / December 20, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been decl...

1 year ago - Accesswire

NexgenRx Inc. Announces Q3 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA

TORONTO, ON / ACCESSWIRE / November 23, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2023, with con...

1 year ago - Accesswire

Nexgenrx Announces Q2 2023 Quarterly Results (With Continued Revenue Growth), Consulting Agreement and Option Grant

TORONTO, ON / ACCESSWIRE / August 21, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2023, with continued...

1 year ago - Accesswire

NexgenRx Announces Q1 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA and Announces Election of New Director

TORONTO, ON / ACCESSWIRE / May 18, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2023, with revenues gro...

2 years ago - Accesswire

NexgenRx Announces 2022 Year End Results With Continued Revenue Growth And Positive EBITDA

TORONTO, ON / ACCESSWIRE / April 6, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2022, once again hi...

2 years ago - Accesswire

NexgenRx Announces Q3 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Free Cash Flow

TORONTO, ON / ACCESSWIRE / November 29, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2022, highligh...

2 years ago - Accesswire

NexgenRx Announces Q2 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Increased Free Cash Flow

TORONTO, ON / ACCESSWIRE / August 18, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2022, highlighted by...

2 years ago - Accesswire

Nexgenrx Announces Q1 2022 Financial Results with Continued Growth in Net Income, EBIDTA and Revenue

TORONTO, ON / ACCESSWIRE / May 17, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") (TSXV:NXG) is pleased to announce its interim financial results for the first quarter ended March 31, 2022, highli...

3 years ago - Accesswire

NexgenRx Announces 2021 Year End Results with Significant Revenue Growth and $3.5m EBITDA

TORONTO, ON / ACCESSWIRE / March 25, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the year ended December 31, 2021, highlighted by 12.01% ...

3 years ago - Accesswire

NexgenRx Announces Financial Results for Q3 2021 with Increased Positive EBITDA and Free Cash Flow

TORONTO, ON / ACCESSWIRE / November 19, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2021.

3 years ago - Accesswire